ADVERTISEMENT
Oblate-Covered Everolimus Reduces Stomatitis in Patients With Metastatic RCC
Oblate-covered everolimus improved the incidence rate and reduced time to stomatitis grade ≥2 in patients with metastatic renal cell carcinoma (mRCC), study findings show (Anticancer Res. 2019;39[7]:3937-3944).
The purpose of the study by Jae-Lyun Lee, MD, PhD, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, and colleagues was to assess the efficacy of wrapping oblate in preventing everolimus-related stomatitis in patients with mRCC.
The primary end points of the study, which included 79 patients with mRCC who did not respond to treatment with VEGF tyrosine kinase inhibitors, were incidence of and time to stomatitis grade ≥2.
Participants in the study were given everolimus that was or was not covered with oblate (oblate arm, n = 42; nonoblate arm, n = 37). Dr Lee et al also reviewed whether stomatitis grade ≥2 that patients in the nonoblate arm had could be prevented with crossover application of oblate.
Ultimately, 30 (38%) patients had stomatitis grade ≥2, including 13 (31%) patients in the oblate arm and 17 (46%) patients in the nonoblate arm (P = .245). The median time to stomatitis grade ≥2 was not reached in the oblate arm and 6.0 months in the nonoblate arm (P = .251).
Among 10 patients in the nonoblate arm with stomatitis grade ≥2 given oblate-covered everolimus, 9 (90%) completely recovered or improved to grade 1 stomatitis, which persisted until everolimus discontinuation.
“Oblate-covered everolimus improved the incidence of and time to grade 2 or more stomatitis, although it was not statistically significantly different compared to the non-oblate group,” Dr Lee and colleagues said.
“Oblate wrapping prevented recurrence of grade 2 or more stomatitis in patients who took uncovered everolimus and developed significant stomatitis,” they concluded.—Hina Porcelli
